Edition:
United States

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

0.98USD
12 Dec 2018
Change (% chg)

$-0.01 (-1.21%)
Prev Close
$0.99
Open
$0.98
Day's High
$0.98
Day's Low
$0.98
Volume
9,946
Avg. Vol
34,227
52-wk High
$3.70
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Soligenix Reports Q1 Loss Per Share Of $0.27
Friday, 11 May 2018 06:00am EDT 

May 11 (Reuters) - Soligenix Inc ::SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.27.Q1 REVENUE $1.1 MILLION VERSUS $1.3 MILLION.  Full Article

Soligenix ‍Says As Of Dec. 31, 2017, Cash Position Was $7.8 Mln​
Thursday, 15 Mar 2018 06:00am EDT 

March 15 (Reuters) - Soligenix Inc ::SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND YEAR-END 2017 FINANCIAL RESULTS.SOLIGENIX INC - ‍AS OF DECEMBER 31, 2017, CASH POSITION WAS $7.8 MILLION​.  Full Article

Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule
Thursday, 21 Dec 2017 06:00am EST 

Dec 21 (Reuters) - Soligenix Inc ::SOLIGENIX IDENTIFIES BIOMARKERS FOR RICIN TOXIN VACCINE TESTING UNDER THE FDA ANIMAL RULE.SOLIGENIX INC - BIOMARKERS FOR RICIN TOXIN VACCINE TESTING BEEN SUCCESSFULLY IDENTIFIED, FACILITATING POTENTIAL APPROVAL UNDER FDA "ANIMAL RULE".SOLIGENIX INC - FURTHER EFFICACY STUDIES IN NHPS EVALUATING POTENTIAL DOSING REGIMENS ARE ANTICIPATED IN 2018.SOLIGENIX - RIVAX DEMONSTRATED REDUCED NUMBER OF VACCINATIONS MAY BE REQUIRED TO ESTABLISH PROTECTION, POTENTIALLY UTILIZING ONLY 2 DOSES INSTEAD OF 3.  Full Article

‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2
Monday, 13 Nov 2017 04:25pm EST 

Nov 13 (Reuters) - Soligenix Inc :‍Knoll Capital Management LP​ reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing.  Full Article

‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​
Tuesday, 7 Nov 2017 03:12pm EST 

Nov 7 (Reuters) - ‍ACT Capital Management LLLP::‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​.  Full Article

Soligenix reports Q3 loss per share $0.17
Monday, 6 Nov 2017 06:00am EST 

Nov 6 (Reuters) - Soligenix Inc :Soligenix announces recent accomplishments and third quarter 2017 financial results.Q3 loss per share $0.17.Q3 revenue $1.82 million versus $2.96 million.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Soligenix announces $1.5 mln NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942
Wednesday, 20 Sep 2017 06:00am EDT 

Sept 20 (Reuters) - Soligenix Inc :Soligenix announces $1.5 million NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer.  Full Article

Soligenix announces $1.5 mln NCI SBIR grant award supporting the phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma
Monday, 18 Sep 2017 06:01am EDT 

Sept 18 (Reuters) - Soligenix Inc :Soligenix announces $1.5 million NCI SBIR grant award supporting the pivotal phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma.  Full Article

Soligenix receives $2.5 mln in additional Niaid funding to advance development of heat stable ricin vaccine
Monday, 14 Aug 2017 06:00am EDT 

Aug 14 (Reuters) - Soligenix Inc :Soligenix receives $2.5m in additional Niaid funding to advance development of heat stable ricin vaccine.Soligenix Inc - ‍National Institute of Allergy and Infectious Diseases has exercised an option to fund good manufacturing practices compliant rivax​.  Full Article

Soligenix reports Q2 loss per share $0.41
Friday, 11 Aug 2017 06:00am EDT 

Aug 11 (Reuters) - Soligenix Inc :Soligenix announces recent accomplishments and second quarter 2017 financial results.Q2 loss per share $0.41.Q2 revenue $1.0 million versus I/B/E/S view $1.1 million.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Soligenix Inc - ‍as of June 30, 2017, company's cash position was $5.8 million.​.  Full Article